Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (12006)	12/28/2018 11:43:23 AM
From: A.J. Mullen	Read Replies (2) \| Respond to of 12215

Illumina bought Solexa, a small British sequencing company of which I owned a little. I happily took a tidy profit - to my lasting regret. Living in San Diego I've come across a number of ILMN executives past and present. At least three of them have told me the purchase of Solexa was the making of their company. I bought back, and sold again when I wanted less exposure in general and there were concerns about government money for research, another bad move. I got back in much too late but at least I did buy back, taking some profit in the summer. Illumina dominates the market for DNA sequencing machines. Pacific Biosciences created a splash criticizing Illumina's method of analyzing short sequences then reconstructing by computation. They claimed the method left significant gaps and created errors. From what I could gather, there was a problem but it would only be significant in a small number of predictable cases. Illumina bought Pacific Biosciences this year. Illumina is the epitome of a biotech heavyweight. Its fortunes will rise and fall with DNA sequencing, and I'm bullish about that. The companies that buy their machines will be more exciting. Many will outpace ILMN, more will fail. Shovels for goldminers is an overworked metaphor, and there was no IP around shovels. Ashley